Binge Eating Disorder Clinical Trial
Official title:
Evaluation of a 12-Week Web-Based Intervention for Binge Eating Disorder: A Randomized Controlled Trial
Verified date | November 2023 |
Source | Heidelberg University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effectiveness of a web-based intervention specifically designed for patients with Binge Eating Disorder (BED) in a blinded randomized controlled trial. After a sign-up process, a diagnostic interview, and a baseline assessment, eligible participants will be randomly allocated either to (1) an intervention group including the online web-based intervention for BED or (2) a waitlist control group with delayed access to the intervention (12 weeks). The program comprises six mandatory weekly sessions and six modular specialization areas resulting in a treatment period of 12 weeks. Minimal guidance is provided via a chat function. Assessments will be conducted at pretreatment (study entrance), six weeks after baseline (mid-treatment), and 12 weeks after baseline (post-treatment). The investigators expect that the intervention group will show lower frequencies of binge eating episodes as the primary outcome variable after the 12 weeks of treatment compared to a waitlist control condition. Moreover, the investigators assume that there will be a higher reduction in global eating disorder symptoms, comorbid psychopathology, and a higher increase in well-being and self-esteem over 12 weeks in the intervention group compared to the waitlist control group. Finally, the investigators expect that the intervention group will demonstrate a significantly higher reduction in functional impairment, substantially better restoration of work capacity, and an improved ability to regulate emotions after the 12 weeks of treatment.
Status | Completed |
Enrollment | 152 |
Est. completion date | August 3, 2022 |
Est. primary completion date | August 3, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion criteria: - sufficient German language skills (C1) - permanent internet access during the study period - meeting the diagnostic criteria for Binge Eating Disorder according to the Diagnostic- and Statistical Manual of Mental Disorders (DSM-5) Exclusion criteria: - current severe depressive episode - acute suicidality - comorbid bipolar disorder or psychotic disorders - acute substance dependence - current psychotherapy or pharmacotherapy for eating disorders - Body Mass Index (BMI) below 18.5 |
Country | Name | City | State |
---|---|---|---|
Germany | Heidelberg University | Heidelberg | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
Heidelberg University | Selfapy GmbH |
Germany,
Berg KC, Peterson CB, Frazier P, Crow SJ. Psychometric evaluation of the eating disorder examination and eating disorder examination-questionnaire: a systematic review of the literature. Int J Eat Disord. 2012 Apr;45(3):428-38. doi: 10.1002/eat.20931. Epub 2011 Jul 8. — View Citation
Bohn K, Doll HA, Cooper Z, O'Connor M, Palmer RL, Fairburn CG. The measurement of impairment due to eating disorder psychopathology. Behav Res Ther. 2008 Oct;46(10):1105-10. doi: 10.1016/j.brat.2008.06.012. Epub 2008 Jul 2. — View Citation
Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses. Value Health. 2015 Sep;18(6):753-8. doi: 10.1016/j.jval.2015.05.009. Epub 2015 Aug 20. — View Citation
Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory--European Version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Br J Psychiatry Suppl. 2000;(39):s28-33. doi: 10.1192/bjp.177.39.s28. — View Citation
Gratz, K. L., & Roemer, L. (2004). Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. Journal of psychopathology and behavioral assessment, 26(1), 41-54.
Izadpanah S, Barnow S, Neubauer AB, Holl J. Development and Validation of the Heidelberg Form for Emotion Regulation Strategies (HFERST): Factor Structure, Reliability, and Validity. Assessment. 2019 Jul;26(5):880-906. doi: 10.1177/1073191117720283. Epub 2017 Jul 21. — View Citation
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. — View Citation
Munsch S, Biedert E, Meyer A, Michael T, Schlup B, Tuch A, Margraf J. A randomized comparison of cognitive behavioral therapy and behavioral weight loss treatment for overweight individuals with binge eating disorder. Int J Eat Disord. 2007 Mar;40(2):102-13. doi: 10.1002/eat.20350. — View Citation
Roth, M., Decker, O., Herzberg, P. Y., & Brähler, E. (2008). Dimensionality and norms of the Rosenberg Self-Esteem Scale in a German general population sample. European Journal of Psychological Assessment, 24(3), 190-197.
Rozental A, Kottorp A, Forsstrom D, Mansson K, Boettcher J, Andersson G, Furmark T, Carlbring P. The Negative Effects Questionnaire: psychometric properties of an instrument for assessing negative effects in psychological treatments. Behav Cogn Psychother. 2019 Sep;47(5):559-572. doi: 10.1017/S1352465819000018. Epub 2019 Mar 15. — View Citation
Schroder J, Sautier L, Kriston L, Berger T, Meyer B, Spath C, Kother U, Nestoriuc Y, Klein JP, Moritz S. Development of a questionnaire measuring Attitudes towards Psychological Online Interventions-the APOI. J Affect Disord. 2015 Nov 15;187:136-41. doi: 10.1016/j.jad.2015.08.044. Epub 2015 Aug 28. — View Citation
Schulte D. Patients' outcome expectancies and their impression of suitability as predictors of treatment outcome. Psychother Res. 2008 Jul;18(4):481-94. doi: 10.1080/10503300801932505. — View Citation
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. — View Citation
Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167-76. doi: 10.1159/000376585. Epub 2015 Mar 28. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in attitudes towards psychological online interventions | Two subscales of the Attitudes Towards Psychological Online Interventions Scale (APOI; Schroeder et al., 2015) will be used. These capture technologization threat and perceived anonymity benefits using 8 items on a 5-point scale. Higher values indicate a more positive attitude towards psychological online interventions. | 0 weeks, 12 weeks | |
Other | Changes in patient outcome expectancies | The Patients' Therapy Expectation and Evaluation Scale (PATHEV; Schulte, 2008) consists of 16 items answered on a 5-point scale. The overall score ranges from 0 to 5. Higher values indicate more positive expectancies towards the therapy. | 0 weeks, 6 weeks (intervention group), 12 weeks | |
Other | Negative intervention effects | The Negative Effects Questionnaire (NEQ; Rozental et al., 2019) consists of 32 items. For each item, the participants answer whether the adverse effect occurred (yes/no), how strong the negative effect was (0 to 4) and whether they attribute the negative effect on the treatment or something else. Two scores can be obtained, one for the frequency of adverse effects due to treatment, ranging from 0 to 32, and one for the negative impact, ranging from 0 to 128. Higher values indicate a higher level of adverse effects. | 6 weeks (intervention group), 12 weeks | |
Other | Use of other healthcare services | The Client Sociodemographic Service Receipt Inventory - European Version (CSSRI-EU; Chisholm et al., 2000) allows assessing the number and length of using different types of healthcare services. Higher values indicate a higher number and frequency of healthcare service usage. | 0 weeks, 6 weeks, 12 weeks | |
Primary | Changes in the frequency of binge eating episodes within the last 28 days | The Eating Disorders Examination Questionnaire (EDE-Q; Berg et al., 2012) captures the frequency of binge eating episodes within the last 28 days using 3 items. Higher values indicate a higher frequency of binge eating episodes. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in global eating psychopathology | The Eating Disorders Examination Questionnaire (EDE-Q; Berg et al., 2012) allows assessing global eating psychopathology based on 22 items. Mean scores range from 0 to 6, with higher values indicating a higher global eating psychopathology. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in the weekly frequency of binge eating episodes and regular eating | The Weekly Binges Questionnaire (WBQ; Munsch et al., 2007) assesses the frequency of binge eating episodes, compensatory behavior, and regular eating by asking participants to count the number of binge eating episodes, the number of compensatory behaviors, and the number of days with regular eating habits. While a higher number of binges and compensatory behaviors indicates a higher symptomatology, a higher number of regular eating days indicates a lower symptomatology. | 0 weeks, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks | |
Secondary | Changes in everyday eating disorder symptoms | Ecological momentary assessment (EMA) of eating disorder symptoms (shape concerns, weight concerns, binge eating episodes, urges to eat) for five days (five signal-contingent measurements and additional event-contingent assessments) | 0 weeks, 12 weeks | |
Secondary | Changes in eating-disorder-related daily difficulties | The Clinical Impairment Assessment Questionnaire (CIA; Bohn et al., 2008) consists of 16 items answered on a 4-point Likert scale. The overall score ranges from 0 to 48. Higher values indicate a higher level of clinical impairment. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in comorbid depressive symptoms | The Patient Health Questionnaire (PHQ-9; Kroenke et al., 2001) consists of 9 items answered on a 4-point scale. The overall score ranges from 0 to 27. Higher values indicate a higher level of depressive symptomology. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in comorbid anxiety symptoms | The General Anxiety Disorder Scale (GAD-7; Spitzer et al., 2006) consists of 7 items answered on a 4-point scale. The overall score ranges from 0 to 21. Higher values indicate a higher level of anxiety symptoms. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in well-being | The World Health Organization Well-Being Index (WHO-5; Topp et al., 2015) consists of 5 items answered on a 6-point scale. The overall score ranges from 0 to 100. Higher values indicate a higher level of well-being. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in self-esteem | The Rosenberg Self-Esteem Scale (RSES; Roth et al., 2008) consists of 10 items answered on a 4-point scale. The overall score ranges from 0 to 30. Higher values indicate a higher level of self-esteem. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in work capacity | The iMTA Productivity Cost Questionnaire (iPCQ; Bouwmans et al., 2015) consists of 12 items grouped in general questions about paid work and questions about productivity losses in paid and unpaid work. The questionnaire captures the missed work time (paid and unpaid) in hours for short-term absence and calendar days for long-time absence and the hours of lost productivity due to presenteeism. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in emotion regulation frequencies | The Heidelberg Form for Emotion Regulation Strategies (HFERST; Izadpanah et al., 2019) consists of 28 items answered on a 5-point scale. For each of the eight emotion regulation strategies (rumination, reappraisal, acceptance, problem solving, suppression of emotional expression, suppression of emotional experience, avoidance, social support), a score ranging from 1 to 5 can be calculated. Higher values indicate a higher frequency of emotion regulation strategy endorsement. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in emotion regulation difficulties | The Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004) consists of 36 items answered on a 5-point scale. The overall score ranges from 36 to 180. Higher values indicate a higher level of emotion regulation difficulties. | 0 weeks, 6 weeks, 12 weeks | |
Secondary | Changes in everyday emotion regulation | Ecological momentary assessment (EMA) of affect, emotion regulation strategies and difficulties for five days (five signal-contingent measurements, and additional event-contingent assessments) | 0 weeks, 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
Active, not recruiting |
NCT01837953 -
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
|
N/A | |
Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT01552759 -
Appetite Hormones in Binge Eating Disorder
|
N/A | |
Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT03107026 -
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 |